Skip to content
Politically.com Search all
Menu

2025 · 1st Quarter (Jan 1 - Mar 31)

GILEAD SCIENCES INC

Filed by GILEAD SCIENCES, INC..

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-09-16 06:26:08 UTC.

Source-reported fields

Filing overview

Type
1st Quarter - Report
Posted
Apr 21, 2025
Income
Not reported
Expenses
$1,662,000.00
Filing UUID
82a83572-365f-4d5f-ab50-f367c653b91c
Termination date
Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

TRD · Trade (domestic/foreign)

International trade and protection of intellectual property; TRIPS Waiver; global supply chain issues, including the Medical Supply Chain Resiliency Act; compulsory licensing and other IP issues in multiple countries.

HCR · Health Issues

Advocate on drug pricing proposals and proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR reauthorization; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes to Notice of Benefit and Payment Parameters (NBPP). Highlight Gilead's efforts to ensure diversity in clinical trials. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage.

MMM · Medicare/Medicaid

Advocate for provisions modifying the Inflation Reduction Act. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules related to hospital inpatient payments, Medicaid Drug Rebate Program, and Value-Based Purchasing arrangements including changes to best price.

CPT · Copyright/Patent/Trademark

Issues related to pharmaceuticals and intellectual property protection including technology transfer, patent rights and funding.

BUD · Budget/Appropriations

Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals.

TAX · Taxation/Internal Revenue Code

Legislative and regulatory proposals to change international and domestic corporate tax law and policy.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.